Alnylam Pharmaceuticals (ALNY) has had the highest return since January 1, 2025 by a large-cap US stock in the Biotechnology Industry, returning 82.8%.
| ASSET | % RETURN |
|---|---|
Alnylam Pharmaceuticals (ALNY) | 82.83% |
Insmed (INSM) | 61.27% |
BeiGene (ONC) | 58.77% |
Summit Therapeutics (SMMT) | 57.21% |
Ascendis Pharma A-S (ASND) | 42.24% |
Gilead Sciences (GILD) | 31.91% |
AbbVie (ABBV) | 14.25% |
Incyte (INCY) | 13.66% |
Exelixis (EXEL) | 11.54% |
Amgen (AMGN) | 10.59% |
argenx NV ADR (ARGX) | 2.64% |
Haleon (HLN) | 0.69% |
Genmab A-S (GMAB) | -0.24% |
Natera (NTRA) | -1.16% |
BioNTech SE (BNTX) | -4.93% |
Vertex Pharmaceuticals (VRTX) | -7.11% |
Neurocrine Biosciences (NBIX) | -9.55% |
Biomarin Pharmaceutical (BMRN) | -13.9% |
United Therapeutics (UTHR) | -14.73% |
Biogen (BIIB) | -16.8% |
Regeneron Pharmaceuticals (REGN) | -24.06% |
Large-cap stocks are treated as having a market cap of $10B+.
